Survival and Glycemic Control in Patients With Coexisting Melanoma and Diabetes Mellitus

Abstract

Aim:Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control.Materials & methods:Patients with melanoma with and without DM were matched 1:1 (2005–2016). Kaplan–Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A1c (HbA1c) and glucose measures over time.Results:Mean HbA1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81–99%) for patients with DM and 63% (95% CI: 51–79%) for patients without DM (p = 0.02).Conclusion:Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM.

Survival and Glycemic Control in Patients With co-existing Squamous Cell Carcinoma and Diabetes Mellitus

“…The statistical analyses conducted were similar to those used for our previous studies [13][14][15][16][17][18][19][20]. Patients with DM (cases) and without DM (controls) were compared on the basis of patient demographic and clinical variables.…”

“…Our findings found statistical significance compared with the other multiple case-control studies done at our institution. The authors had previously investigated the effect of solid tumors -breast, lung, prostate, colorectal, pancreatic, gastric, esophageal, lymphoma and melanoma and DM on patient outcome measures [13][14][15][16][17][18][19][20]. In all these case-control studies, DM did not affect survival of patients.…”

“…Previous studies from our institution have evaluated the relationship between patients with DM and several malignancies including melanoma, pancreatic cancer, lung cancer, breast cancer, prostate cancer, gastroesophageal cancer, colorectal cancer and lymphoma [13][14][15][16][17][18][19][20]. Only gastroesophageal cancer has shown a decrease in survival in patients with DM compared with those without [18].…”

Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study

“…The only exception was for patients with gastroesophageal cancers, where we did find that patients with preexisting DM had a higher risk of death than those without DM [ 26 ]. For patients with melanoma, our analyses revealed an unexpected increase in progression-free survival in the DM group compared with the non-DM group [ 27 ]. The reasons for these differences are not clear; however, further studies should continue to explore these associations, as worldwide incidence of DM continues to rise.…”

Survival and Glycemic Control in Patients with Coexisting Lymphoma and Diabetes: A Case–Control Analysis

“…Previous case–control studies of patients at a large cancer institute in the southwestern USA have shown that diabetes does not worsen survival for patients with solid organ cancers and that solid organ cancers do not worsen glycemic control. We have studied this relationship in pancreatic cancer [ 15 ], gastroesophageal cancer [ 16 ], lung cancer [ 17 ], breast cancer [ 18 ], prostate cancer [ 15 ], colorectal cancer [ 19 ] and melanoma [ 20 ]. Gastroesophageal cancer was the only cancer in which a greater risk of death was seen in patients with than without diabetes [ 16 ].…”